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Available online 17 April 2016Cardiac hypertrophy is associated with growth and functional changes of cardiomyocytes, including mitochon-
drial alterations, but the latter are still poorly understood. Here we investigated mitochondrial function and dy-
namic localization in neonatal rat ventricular cardiomyocytes (NRVCs) stimulatedwith insulin like growth factor
1 (IGF1) or phenylephrine (PE), mimicking physiological and pathological hypertrophic responses, respectively.
A decreased activity of themitochondrial electron transport chain (ETC) (state 3)was observed in permeabilized
NRVCs stimulated with PE, whereas this was improved in IGF1 stimulated NRVCs. In contrast, in intact NRVCs,
mitochondrial oxygen consumption rate (OCR) was increased in PE stimulated NRVCs, but remained constant
in IGF1 stimulated NRVCs. After stimulation with PE, mitochondria were localized to the periphery of the cell.
To study the differences in more detail, we performed gene array studies. IGF1 and PE stimulated NRVCs did
not reveal major differences in gene expression of mitochondrial encoding proteins, but we identiﬁed a gene
encoding a motor protein implicated in mitochondrial localization, kinesin family member 5b (Kif5b), which
was clearly elevated in PE stimulated NRVCs but not in IGF1 stimulated NRVCs. We conﬁrmed that Kif5b gene
and protein expression were elevated in animal models with pathological cardiac hypertrophy. Silencing of
Kif5b reverted the peripheral mitochondrial localization in PE stimulated NRVCs and diminished PE induced
increases in mitochondrial OCR, indicating that KIF5B dependent localization affects cellular responses to PE
stimulated NRVCs.
These results indicate that KIF5B contributes to mitochondrial localization and function in cardiomyocytes and
may play a role in pathological hypertrophic responses in vivo.







Cardiac hypertrophy is believed to be an adaptive response of the
heart aimed at reducing wall stress and maintaining cardiac function.
Cardiac hypertrophy can be broadly divided into pathological and phys-
iological hypertrophy. Both types of hypertrophy are associated with
growth and functional changes of cardiomyocytes, but pathological
hypertrophy may result in cardiac decompensation and heart failure
[1,2].
Physiological hypertrophy can be induced by growth factors, like
insulin-like growth factor (IGF1), whereas adrenergic signaling and
angiotensin II can stimulate pathological hypertrophy. Although thegy, University Medical Center
GZ Groningen, P.O. Box 30.001,
. This is an open access article undercommon outcome of these hypertrophic signals is cardiomyocyte
growth (hypertrophy), these responses are associated with distinct in-
tracellular signaling pathways and different structural and functional
consequences [3]. Among different events, like ﬁbrosis andmicrovascu-
lar abnormalities [3,4], energy metabolic reprogramming also appears
to be disparate between the two hypertrophic conditions [5]. This in-
cludes alterations in substrate usage and mitochondrial function [3].
The metabolic switch from fatty acids to glucose usage, which is
observed in pathological hypertrophy, has been investigated in great
detail [6–8]. The changes in mitochondrial dynamics and function on
the other hand are still vague. The general view is that physiological
factors stimulate mitochondrial biogenesis and hence mitochondrial
capacity [9], whereas pathological stimulation results in altered mito-
chondrial dynamics and activity [10]. These changes are still far from
understood and differences in etiology, hypertrophic state (compensat-
ed/decompensated) and methodology have probably contributed to
different results [11]. Moreover, the complexity of the cardiovascular
system in which (neuro)hormonal signals, biomechanical changes,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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pact on hypertrophy development and mitochondrial function most
likely hampers these studies.
In this study we aimed to investigate mitochondrial function in a
simpliﬁed system using cultured neonatal rat cardiomyocytes (NRVCs)
and mimicked physiological and pathological hypertrophy with IGF1
and phenylephrine (PE), respectively. We show that a pathological
stimulus (PE) can induce changes in mitochondrial function and dy-
namic localization within 24 h of stimulation. In contrast to IGF1 stimu-
lated NRVCs, in PE stimulated NRVCs the kinesin motor protein KIF5B
was upregulated. This results in abnormal andmore peripheral localiza-
tion of the mitochondria. Depletion of KIF5B prevented this mitochon-
drial redistribution and also partially inhibits the mitochondrial
respiratory increase and hypertrophic response observed after stimula-
tionwith PE. This indicates that KIF5B is involved in PE induced changes
inmitochondrial localization and function and suggests that KIF5B could
play a role in energetic changes in pathological hypertrophic responses.
2. Materials and methods
2.1. Ethics statement
All experiments were approved by the Committee on Animal
Experimentation of the University of Groningen and were conducted
under international guidelines on animal experimentation conforming
to the Guide for the Care and Use of Laboratory Animals published by
the Directive 2010/63/EU of the European Parliament.
2.2. Isolation and culturing of primary cardiomyocytes
Primary neonatal rat ventricular cardiomyocytes (NRVCs) were iso-
lated from Sprague Dawley neonatal rats of 1–3 days old, as previously
described [12,13]. NRVCs were grown in Dulbecco's Modiﬁed Eagle
Medium (DMEM) supplemented with 5% fetal calf serum (FCS) and
penicillin–streptomycin (100 U/ml–100 μg/ml). NRVCs were serum
starved in DMEM with penicillin–streptomycin (100 U/ml–100 μg/ml)
48 h after isolation. After 24 h of starvation NRVCs were stimulated
with 50 μM phenylephrine (PE) or 10 nM insulin-like growth factor 1
(IGF1) (Life Technologies) for 24 h. All media and supplements were
purchased from Sigma-Aldrich Chemie B.V., Zwijndrecht, The
Netherlands. After stimulation, NRVCs were washed twice with PBS
and used for further analysis.
2.3. Immunoﬂuorescence microscopy
NRVCs were grown on coverslips coated with laminin (Millipore,
Amsterdam, The Netherlands) and treated as described above. NRVCs
were ﬁxed for 10 min with 4% paraformaldehyde at 4 °C, followed by
permeabilization with 0.3% Triton X for 5 min. For cell size measure-
ments, NRVCs were incubated with monoclonal anti-alpha-actinin
antibody (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands)
in 3% BSA, 2% normal goat serum, and 0.1% Tween in PBS for 1 h at RT.
NRVCs were washed with PBS and incubated for another hour with a
goat anti-mouse ﬂuorescein isothiocyanate (FITC) secondary antibody
(Santa-Cruz Biotechnology, Heidelberg, Germany). Coverslips were
mounted with mounting medium containing 4′,6-diamidino-2-
phenylindole dihydrochloride (DAPI) (Vector Laboratories, Burlingame,
CA, USA) for counterstaining of the nuclei. Slides were imaged using a
Leica DMI6000B inverted immunoﬂuorescence microscope and cell
size was determined using ImageJ analysis software. To determine
mitochondrial localization the same staining protocol was followed as
described above, but next to alpha-actinin staining, anti-TOM20
antibody staining was performed (Santa Cruz, Heidelberg, Germany).
To obtain a quantitative measure of mitochondrial distribution in the
cytosol, the intensity of TOM20 staining was determined in a circular
area at the nuclear periphery (perinuclear) and an identical sized areaat the cell membrane (cellular periphery) using ImageJ software.
These regions were never overlapping. The intensity ratio for
perinuclear versus peripheral TOM20 staining was determined and at
least 25 NRVCs/condition were analyzed in at least three independent
experiments. The percentage of NRVCs with a perinuclear to peripheral
ratio above 3.0 was determined. Detailed microscopy images were
generated using a Delta Vision Elite system using a 60× objective at
the UMCG imaging center. Z-stacks were generated and images were
deconvolved by 5 iterations and subsequently a Z-projection was
generated.
2.4. [3H]-leucine incorporation
NRVCs were grown in 12-well plates and L-[4.5-3H]leucine (1 μCi/
ml, PerkinElmer) was added to the medium right after stimulation
with PE or IGF1. NRVCs were cultured for an additional 24 h and
L-[4.5-3H]leucine incorporation was determined as previously
described [12].
2.5. Quantitative real time PCR
Total RNA was isolated using a nucleospin RNA II kit (Bioke, Leiden,
The Netherlands) and cDNA was synthesized using QuantiTect Reverse
Transcriptional kit (Qiagen, Venlo, The Netherlands) according to the
manufacturer's instructions. Relative gene expression was determined
by quantitative real time PCR (qRT-PCR) on the Bio-Rad CFX384 real
time system (Bio-Rad, Veenendaal, The Netherlands) using ABsolute
QPCR SYBR Green mix (Thermo Scientiﬁc, Landsmeer, The
Netherlands). Gene expressions were corrected for reference gene
values (Rplp0), and expressed relative to the control group. Primer
sequences used are depicted in Supplemental Table 1.
2.6. Western blot
Western blotting was performed as described previously [14]. In
brief, protein was isolated with radio-immunoprecipitation assay
(RIPA) buffer (50 mM Tris pH 8.0, 1% nonidet P40, 0.5% deoxycholate,
0.1% SDS, 150 mM NaCl) supplemented with 40 μl/ml phosphatase
inhibitor cocktail 1 (Sigma-Aldrich Chemie B.V., Zwijndrecht, The
Netherlands), 10 μl/ml protease inhibitor cocktail (Roche Diagnostics
Corp., Indianapolis, IN, USA) and 1 mM phenylmethylsulfonyl ﬂuoride
(PMSF) (Roche Diagnostics Corp., Indianapolis, IN, USA). Protein con-
centrations were determined with a DC protein assay kit (Bio-Rad,
Veenendaal, TheNetherlands). Equal amounts of proteinswere separat-
ed by SDS-PAGE and proteins were transferred onto polyvinylidene
diﬂuoride (PVDF) membranes. (The following antibodies were used:
anti-OXPHOS cocktail (MitoSciences, Eugene, Oregon, USA), anti-pAKT
(Cell Signaling Technology Danvers, MA, USA), anti-total AKT (Cell Sig-
naling Technology Danvers, MA, USA), anti-beta-actin (Sigma-Aldrich
Chemie B.V., Zwijndrecht, The Netherlands), anti-Kif5b anti-Mitofusin-
1 (Abcam Cambridge, UK), anti-Drp1 (Becton Dickinson, Breda, The
Netherlands) and anti-TOM20 (Santa Cruz, Heidelberg, Germany).
After incubation with HRP-conjugated secondary antibodies, signals
were visualizedwith ECL and analyzedwith densitometry (ImageQuant
LAS4000, GE Healthcare Europe, Diegem, Belgium). Cardiac troponin T
(cTnT) was used as a loading control as described before [15].
2.7. Seahorse mitochondrial ﬂux analyses
To determine the mitochondrial oxygen consumption rate (OCR) a
Seahorsemetabolic ﬂux analyzer (Seahorse Biosciences, Massachusetts,
USA) was used. A standardized protocol [16] was used to determine
speciﬁc mitochondrial complex activities in permeabilized cells. To
measure complex I and complex II mediated respiratory activities,
cardiomyocytes were permeabilized using recombinant perfringolysin
O (rPFO) (XF-plasma membrane permeabilizer (PMP) reagent)
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described above. On the day of analysis, NRVCs were washed twice
with ASBSA (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4,
5 mM KOH, 0.4% BSA). The XFPMP reagent (1 nM) was added together
with the appropriate substrates and inhibitors and the assaywas started
immediately. To measure complex I activity, pyruvate (5 mM) and
malate (2.5 mM) were added to the MAS–BSA solution. For complex II
mediated respiration rotenone (1 μM) and succinate (10 mM) were
used. The OCR was measured by adding subsequently ADP (1 mM),
oligomycin (1 μg/μl) and FCCP (1 μM). Non-mitochondrial OCR was
measured after the addition of antimycin/rotenone (1 μM/1 μM). This
non-mitochondrial respiration was subtracted from the total OCR
values resulting in ADP induced state 3 mitochondrial OCR, ATP-linked
state 4 mOCR and FCCP induced uncoupled mOCR (state 3u).
Determination of the OCR in intact cardiomyocytes with the
Seahorse metabolic ﬂux analyzer was performed as previously
described [17]. Neonatal cardiomyocytes were seeded at a density of
100,000 NRVCs/well in special Seahorse 24-well plates. One hour before
initiation of measurements, medium was replaced with XF medium
supplemented with 10 mM glucose or 1 mM pyruvate and incubated
for 1 h in a CO2 free 37 °C incubator. The basal respiration of the
NRVCs was measured, followed by injection of oligomycin (ATP
synthase inhibitor) (1 μM) to measure the ATP linked OCR. The
uncoupler carbonyl cyanide 4-(triﬂuoromethoxy)phenylhydrazone
(FCCP) (0.5 μM) was used to determine maximal respiration. Finally,
rotenone (1 μM) and antimycin A (AR) (1 μM) were injected to
determine the non-mitochondrial respiration via inhibition of
complexes I and III, respectively. Mitochondrial speciﬁc OCR (mOCR)
was calculated by subtracting the non-mitochondrial respiration AR of
the total OCR values. ATP-linked OCR is the calculated difference
between basal mOCR and mOCR after the addition of oligomycin. In
each plate the same treatmentwas performed in triplicate or quadruple.
The OCR was corrected for the amount of total protein per well as
determined using the Biorad DC Protein Assay (Biorad).
2.8. mtDNA/nDNA ratio
Total DNA, including mitochondrial DNA (mtDNA), was extracted
from NRVCs using the DNA blood and tissue kit (Qiagen, Venlo, The
Netherlands). The isolated DNA showed high purity (A260/
A280 N 1.8), as determined by spectroscopic analysis. To determine
the ratio betweenmitochondrial and nuclearDNA, relative gene expres-
sion was determined by qRTPCR on a Bio-Rad CFX384 real time system
using SYBR Green dye. The expression of the mitochondrial gene
cytochrome b (CytB) was corrected for the expression of the nuclear
gene Trpm2. Primers and procedure have been described before [17].
2.9. Citrate synthase activity
Whole cell citrate synthase activity was measured using an enzyme
assay kit (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands)
according to the manufacturer's instructions and as previously
described by us [17]. In short, cell lysates were prepared using the
CelLytic M Cell Lysis Reagent and protein concentrations were
measured. 3 μg of protein was combined with acetyl coenzyme A,
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) and assay buffer in a 96
well plate. The reaction was initiated by adding oxaloacetate into the
mixture and total activity was measured. Absorbance was measured at
412 nm using a spectrophotometer following a kinetic program.
Triplicate measurements were performed on each sample.
2.10. Gene array
RNA was isolated as described above and 4 independent biological
samples per conditionwere used forwhole genomeexpression analysis.
Biotin-labeling, hybridization, washing and scanning of GeneChip RatGene 1.1 ST arrays (Affymetrics) were performed in expert labs
(Nutrigenomics Consortium, Wageningen, The Netherlands) according
to Affymetrix's protocols. Processing of the data occurred using the
MADMAX pipeline [18]. Array data have been deposited at the Gene
Expression Omnibus (GEO) database (GSE73896). Differentially
expressed gene sets were identiﬁed with the IBMT regularized t-test
[19]. Corrections for multiple testing were done using the false
discovery rate method [20]. A false discovery rate (FDR) of b10% was
considered signiﬁcantly changed. Genes related to the mitochondria
were selected from the gene list with signiﬁcantly regulated genes
(FDR b 10%). These genes were annotated in biological processes using
Database for Annotation, Visualization and Integrated Discovery
(DAVID) software [21]. Biological processes shown are based on Gene
Ontology, GOTERM_BP4. Gene set enrichment analysis [22] was
performed to be able to detect signiﬁcant pathway regulation of gene
sets, thereby not only focusing on signiﬁcantly regulated genes, but tak-
ing into account all expressed genes. A heat map was generated using
statistical and graphical computer software “R”. For the heat map only
motor protein encoding genes were selected that we identiﬁed in the
FDR b 10% gene lists.
2.11. Animal experiments
Expression of Kif5b was analyzed in multiple hypertrophy animal
models. In all animal experiments, animals were kept on a 12 h
light:12 h dark cycle with ad libitum access to food and water. Pressure
overload inmale C57BL/6J mice (Harlan, The Netherlands) was induced
at the age of 8–10 weeks by transverse aortic constriction (TAC). Mice
were terminated at 4 or 8 weeks post-TAC and sham operated animals
were used as controls, as described previously [23]. Homozygous trans-
genic TGR (mREN2)27 rats overexpressmouse renin resulting in hyper-
tension and consequently develop cardiac hypertrophy were used as
described before [13,14,24]. Age- and gender-matched Sprague Dawley
(SD) animals (genetic background strain) served as controls. For induc-
tion of physiological hypertrophy, male C57BL/6J mice were allowed
voluntary wheel running for 10 weeks. Sedentary animals were used
as controls.
2.12. Gene silencing
Silencing of gene expression was performed with oligofectamine
(Dharmacon) according to the manufacturer's instruction. Silencing
was performed with AccuTarget predesigned siRNA 1,664,194 and
1,664,195 from Bioneer targeting rat Kif5b. Control Accutarget siRNA
sequences were also from Bioneer and have been described before [17].
2.13. Statistical analysis
All values are presented as means ± standard deviation (SD).
Comparison of two groups was done using a two-tailed Student's
t-test. One-way ANOVA with posthoc Bonferroni correction was used
to compare the difference between multiple groups. When data were
not normally distributed, a Kruskal Wallis test was performed, followed
by a Mann–Whitney U test for individual comparison of means. SPSS
software (PASW Statistics 22) was used for the statistical analyses.
P b 0.05 was considered to be signiﬁcant.
3. Results
3.1. PE and IGF1 induce different pathways, resulting in similar hypertro-
phic responses in NRVCs
Stimulation of NRVCswith IGF1 and PE resulted in a similar increase
in cell size as is shown in Fig. 1A and B. Also protein synthesis was
signiﬁcantly increased upon stimulation with PE and IGF1, albeit
somewhat stronger with IGF1 (Fig. 1C). The pathological stress markers
Fig. 1. Stimulation of NRVCs with PE or IGF1 induced hypertrophy. NRVCs were stimulatedwith PE or IGF1 for 24 h and hypertrophic responseswere measured. Cell size was determined
by stainingwith the sarcomeric cardiomyocyte speciﬁcmarkerα-actinin (green) and nucleiwere counterstainedwithDAPI (blue). Representative images are shown (A). Quantiﬁcation of
cell surface area of PE or IGF1 stimulated NRVCs relative to control NRVCs (N= 3) (B). Protein synthesis was determined using 3H-leucine incorporation (N= 11) (C). mRNA expression
levels of the hypertrophic markers Nppa, Nppb, Rcan1 and Acta1 were determined using qRT-PCR (N = 6–8) (D). Protein expression levels of phosphorylated Akt and total Akt were
determined by Western blot (N = 7) (E). Representative Western blot images are shown (F). All graphs depict means and SD, *P b 0.05 compared to control; #P b 0.05 compared to
PE stimulated NRVCs. Nppa, atrial natriuretic peptide; Nppb, brain natriuretic peptide; Rcan1, regulator of calcineurin; Acta1, actin alpha1 skeletal muscle.
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stimulated NRVCs (Fig. 1D), but expression did not change upon IGF1
treatment. Acta1was up-regulated upon stimulation with both stimuli
and probably indicates a general response of the cardiomyocytes toFig. 2. Complex II dependent OCR is decreased after PE stimulationwhereas IGF1 stimulation inc
by permeabilizing NRVCs before measuring the OCR using a Seahorse XF24 Extracellular Flu
Sequential addition of ADP, oligomycin, FCCP and antimycin/rotenone (AR) is indicated in th
the subtraction of OCR measured after A/R resulting in mitochondrial speciﬁc OCR. State 3 is
the OCR after the addition of oligomycin, indicating the ATP-independent respiration. State 4
pyruvate and malate as substrates (N = 6) (A)–(B). Complex II dependent OCR was measur
graphs depict means and SD, *P b 0.05 compared to control; #P b 0.05 compared to PE stimulahypertrophic stimulation (Fig. 1D). Whereas IGF1 strongly stimulated
AKT phosphorylation (Fig. 1E and F), PE stimulated Rcan1 expression,
a marker for calcineurin activation. These results demonstrate that
NRVCs show similar growth response upon PE and IGF1 stimulation,reased complex I dependent OCR. Totalmitochondrial complex speciﬁc OCRwas analyzed
x Analyzer. Substrates were included in the buffer and basal respiration was measured.
e graph. Parameters of complex speciﬁc mitochondrial respiration were calculated, after
the OCR after the addition of ADP indicating the maximal coupled respiration. State 4 is
u is induced after the addition of FCCP. Complex I dependent OCR was measured using
ed using succinate as substrates and rotenone to inhibit complex I (N = 6) (C)–(D). All
ted NRVCs.
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reﬂecting the in vivo pathological and physiological differences.
3.2. PE stimulation decreased complex II activity, whereas IGF1 increased
complex I activity
The general perception is that mitochondrial function declines in
pathological cardiac hypertrophy, whereas it improves in physiological
hypertrophy [10,11,25,26]. To investigatewhether this could also be ob-
served in NRVCs in vitro, the mitochondrial complex I and II dependent
respiration in permeabilized NRVCswas determined using the Seahorse
ﬂux analyzer. Either malate/pyruvate was used as a substrate for com-
plex I or succinate/rotenone for complex II. As shown in Fig. 2A and B,
an increase in complex I dependent oxygen consumption rate (OCR)
was observed after stimulation with IGF1, although only state 3 was
signiﬁcantly increased. No increase in complex I dependent OCR was
observed after PE stimulation, rather a trend of lower complex I depen-
dent OCRwas shown. No differences in complex II dependent OCRwere
observed after stimulation with IGF1. Stimulation with PE resulted,
however, in a signiﬁcant diminishment of state 3 activity. Also state 4
and state 3u activities appeared lower after PE stimulation, albeit not
signiﬁcant (Fig. 2C and D). Thus, a speciﬁc pathological or physiological
stimulus can, respectively, decrease and enhance speciﬁcmitochondrial
complex activities in vitro.
3.3. NRVCs stimulated with PE, but not IGF1, have increased cellular
mitochondrial respiration
The Seahorse ﬂux analyzer provides the unique opportunity to
measure mitochondrial OCR also in intact NRVCs. Fig. 3A and B shows
the cellular OCR in control, PE and IGF1 stimulated NRVCs as
determined in intact NRVCs using glucose as a substrate. Interestingly,
cellular OCR was signiﬁcantly higher in PE stimulated NRVCs, as
compared to control and IGF1 stimulated NRVCs (Fig. 3A). Also after
correction for non-mitochondrial OCR (total cellular OCR−A/R insensi-
tive OCR), the mitochondrial speciﬁc OCR after stimulation with PE
showed a signiﬁcant increase of 2 fold as compared with control
NRVCs (Fig. 3B). Addition of the ATP synthase inhibitor oligomycin
revealed that the ATP-linked (oligomycin dependent) OCR was 3.5
fold higher in PE stimulated NRVCs. Maximal respiration induced by
the addition of the uncoupler FCCP was also clearly increased and this
trend was observed in all our experiments (Figs. 3, 8, Supplemental
Figs. 1, 5), albeit not always signiﬁcant. The latter is probably a power
issue. No differences in mitochondrial respiration were observed in
IGF1 stimulated NRVCs, indicating that increased OCR is not aFig. 3.Mitochondrial respiration in intact NRVCs is increased after stimulationwith PE. Total cell
addition of the ATP synthase inhibitor oligomycin, the uncoupling agent FCCP and mitocho
Mitochondrial speciﬁc OCR values were obtained by subtracting OCR values after the additio
OCR. Corrected oxygen consumption data of the ﬁrst 3 measurements were averaged to yield
was calculated. Maximal respiration was induced by FCCP (N= 5) (B). All graphs depict meanprerequisite for hypertrophy development (Fig. 3B). Similar results
were obtained using pyruvate as a substrate, indicating that these
ﬁndings are not a result of changes in glycolysis (Supplemental Fig. 1).
These data show that changes in complex activities do not necessarily
reﬂect the mitochondrial ﬂuxes in intact NRVCs.3.4. Changes in mitochondrial respiration are not due to mitochondrial
biogenesis
Altered mitochondrial biogenesis could explain the observed differ-
ences in the cellularmitochondrial respiration. To excludemitochondri-
al biogenesis as a causal factor underlying these observedmitochondrial
effects several parameters were investigated. Protein expression of the
different complexes of the ETC was not altered in PE and IGF1 stimulat-
ed NRVCs, as shownwith an OXPHOSWestern blot (Fig. 4A and B). Also
the ratio between mtDNA and nDNA, an established measurement of
mitochondrial biogenesis, was similar between control, PE and IGF1
stimulated NRVCs (Fig. 4C). In addition, citrate synthase activity as an
independent measurement of mitochondrial biogenesis was unaltered
(Fig. 4D). This indicates that the observed changes in mitochondrial
respiration were not mediated by increased mitochondrial biogenesis
or increased levels of ETC proteins.3.5. Changed mitochondrial localization in PE treated NRVCs
Although mitochondrial activity has been the main focus in cardiac
energetics formany years, alsomitochondrial dynamics and localization
have increasingly gained interest in the cardiac ﬁeld. Abnormalities
have been described to affect mitochondrial function [27,28]. We
stained NRVCs with an antibody against the mitochondrial outer
membrane protein TOM20 [29]. Microscopic inspection revealed a
strong perinuclear staining in control and IGF1 stimulated NRVCs,
whereas PE stimulated NRVCs showed a more dispersed and cytoplas-
mic mitochondrial staining (Fig. 5A). This effect in PE treated cells was
not simply a reﬂection of increased cell size, since both PE and IGF1
stimulated cells increased equally in size. Quantiﬁcation of the ratio of
perinuclear versus peripheral staining intensity conﬁrmed a high
intensity around the nucleus in control and even more in IGF1
stimulated NRVCs. This ratio was signiﬁcantly lower in PE stimulated
cells (Fig. 5B). Furthermore, counting the number of NRVCs with a low
perinuclear/peripheral staining ratio (b3.0) conﬁrmed this peripheral
localization in PE stimulated NRVCs (Fig. 5C). Thus, PE, but not IGF1,
stimulates peripheral mitochondrial localization in NRVCs.ular OCRwasmeasured using a Seahorse XF24 Extracellular Flux Analyzer, with sequential
ndrial respiration inhibitors antimycin A/rotenone (AR) as depicted in the graph (A).
n of AR from total OCR resulting in mitochondrial respiration, maximal and ATP-linked
the mitochondrial respiration. The ATP-linked OCR, deﬁned as oligomycin-sensitive OCR,
s and SD, *P b 0.05 compared to control.
Fig. 4. Increased mitochondrial respiration is not due to mitochondrial biogenesis. Several independent measurements of mitochondrial biogenesis were assessed in PE and IGF1
stimulated NRVCs. Total cellular protein was blotted and incubated with speciﬁc OXPHOS antibody to assess protein expression levels of the different complexes of the ETC. A
representative Western blot is shown (A) and the expression of the separate complexes was quantiﬁed (N = 11) (B). RT-PCR analysis was used to compare the amount of mtDNA
with nDNA (N = 5) (C). Whole cell citrate synthase activity was measured using an enzyme assay kit (N = 5) (D). All graphs depict means and SD.
75W. Tigchelaar et al. / Journal of Molecular and Cellular Cardiology 97 (2016) 70–813.6. Gene array analysis reveals upregulation of Kif5b in PE treated NRVCs
Gene expression changes could potentially reveal targets that
explain the observed differences. A gene array analysis was therefore
performed with RNA from control, PE and IGF1 stimulated NRVCs.
Using a FDR of 10%, we identiﬁed N300 genes that were differentiallyFig. 5.Mitochondria in PE stimulatedNRVCs are dispersed throughout the cytosol. Mitochondria
were stained with speciﬁc sarcomeric α-actinin (red) and nuclei were counterstained with
perinuclear localized mitochondrial staining as compared to peripheral cytoplasmic mitochon
versus peripheral mitochondrial ﬂuorescence intensity ratio lower than 3 (N = 6) (C). All g
stimulated NRVCs.expressed in PE stimulated NRVCs, compared to almost 1200 genes in
IGF1 stimulated NRVCs. Of these genes at least 4.9% of both the PE and
IGF1 group translated into proteins that are localized to the mitochon-
dria, based on available proteomic data (Fig. 6A) [30]. Thismitochondri-
al set was further explored using DAVID to categorize genes into
biological processes (Fig. 6B). No speciﬁc functionally related groupsl localizationwas visualized by staining NRVCswith anti-TOM20 antibody (green). NRVCs
DAPI (blue). Representative pictures are shown (A). Quantiﬁcation of the intensity of
drial staining (N = 6) (B). Quantiﬁcation of the percentage of NRVCs with a perinuclear
raphs depict means and SD, *P b 0.05 compared to control. #P b 0.05 compared to IGF1
Fig. 6. Analysis of gene expression arrays of control versus PE and IGF1 stimulated NRVCs. Gene expressionwas analyzed using Affymetrics gene expression arrays. RNA of control, PE and
IGF1 stimulated cells was isolated and used for expression analysis (A). Expression of genes encodingmitochondrial proteinswas analyzed. Using a FDR b 10% revealed a number of genes
that were differentially expressed in NRVCs upon stimulation with PE or IGF1 (A). Analysis of the signiﬁcantly regulated genes related to the mitochondria. The number of differentially
expressed genes related to the mitochondria compared to control in PE-treated NRVCs (blue) and IGF1-treated NRVCs (yellow) is depicted in circles, common genes are shown in green.
The biological processes (DAVID) to which these genes are related are shown in respective boxes (B). A simpliﬁed scheme of gene sets that were signiﬁcantly regulated upon stimulation
with PE or IGF1 (C).
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9 speciﬁc PE controlled genes, we identiﬁed upregulation of Bcl2 (anti-
apoptotic) and downregulation of Htra2 (apoptotic), which is in line
with a previously described link between PE and protection against
cardiomyocyte apoptosis [31,32]. Only 6 genes were shared between
PE and IGF1 stimulatedNRVCs, identifying enrichedbiological pathways
in isoprenoid, sterol and cholesterol biosynthetic and metabolic pro-
cesses (Fig. 6B). In IGF1 stimulated NRVCs more mitochondrial relatedgenes were differentially expressed. For the IGF1 gene set functional
annotation revealed enrichment in several metabolic and biosynthetic
processes includingoxoacid, coenzyme, cofactor, organic acid, heterocy-
cle, nucleotide and fatty acid metabolic and biosynthetic processes. No
major changes in speciﬁc ETC related gene expression were observed
(Fig. 6B and Supplemental data set).
Whole gene set enrichment analysis, which allows detection of
changes in gene sets not depending on signiﬁcant changed expression
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matic and simpliﬁed overview of gene sets related to metabolism is
shown in Fig. 6C. A number of changes related to metabolism in IGF1
stimulated NRVCs were observed, including the TCA cycle, the ETC
and the OXPHOS pathways. In PE stimulated NRVCs less changes in
speciﬁc gene sets were found, including fatty acid metabolism (Fig.
6C). Thus, changes in the expression of genes encoding mitochondrial
localized proteins are small in these 24 h PE and IGF1 stimulated NRVCs.
3.7. The kinesinmotor protein KIF5B is speciﬁcally upregulated in PE treated
cells
Based on our localization data, we also investigated genes potential-
ly involved in mitochondrial dynamics and localization. We did notFig. 7. Increased KIF5B expression in animal models of pathological hypertrophy. Based on gen
proteins (FDR b 10%)were identiﬁed in the PE stimulated or IGF1 stimulatedNRVCs. A heat-map
gene expressionwasmeasured by quantitative RT-PCR in cardiac tissue. Kif5b expression inmic
PE stimulation was evaluated by Western blotting and a representative blot from three indep
models, Kif5b gene and protein expression were determined by quantitative RT-PCR and West
surgery (N = 7–12) (C). Quantiﬁcation of KIF5B protein expression in mice after 8 weeks T
transgenic Ren2 rats (N = 8–9) (F). KIF5B protein expression in transgenic Ren2 rats (N = 6
compared to control.observe gene expression differences in genes involved inmitochondrial
ﬁssion/fusion and also protein levels and dynamic localization of two of
these proteins, dynamin-like protein (Drp1) and mitofusin (Mfn1/2)
were not altered (Supplemental Fig. 2). We did, however, identify
several kinesin and dynein motor proteins in our gene array that were
differentially expressed between the different conditions (Fig. 7A).
Most interestingly, Kif5b showed the highest expression and was
upregulated under PE stimulatory conditions only (1.6 fold increase).
Moreover, we could conﬁrm that KIF5B protein levels were similarly in-
creased in PE stimulated cells only (Fig. 7B). KIF5B has previously been
shown to affect localization of themitochondria in tumor cell lines [33].
Also in in vivo hypertrophic conditions disturbed morphology and
mitochondrial localization have been reported [28,34–38].We therefore
analyzed whether Kif5b gene expression was altered in mice withe expression array data described in Fig. 6, differentially expressed genes encoding motor
of these genes is shown (A). To conﬁrmexpression in animalmodels of hypertrophy Kif5b
e after 4 and 8weeks TAC surgery (N=7–12). Expression of Kif5b protein levels after 36 h
endent experiments is shown (B). To conﬁrm expression in animal cardiac hypertrophy
ern blotting, respectively. Cardiac Kif5b gene expression in mice after 4 and 8 weeks TAC
AC surgery (N = 6) (D) and representative Western blot (E). Kif5b gene expression in
) (G) and representative Western blot (H). All graphs depict means and SD, *P b 0.05 as
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and in hypertensive transgenic Ren2 rats. Kif5b gene expression was in-
deed elevated in the animal models with pathological hypertrophy (Fig.
7C and D). Also in this case KIF5B protein levels paralleled the gene ex-
pression increases (Fig. 7C and D). We also like to note that we did not
observe an increase in Kif5b gene expression in a physiological mouse
hypertrophymodel (Supplemental Fig. 3). Together these data suggests
that KIF5B could control mitochondrial dynamic localization in cardiac
tissue in response to pathological hypertrophic stimuli.Fig. 8. Kif5b silencing in NRVCs affects mitochondrial localization. Kif5bwas silenced in NRVCs
stimulated NRVCs (N = 6) (A). Protein expression levels were measured by Western blot
experiments is shown (B). Mitochondrial localization is visualized by staining mitochondria
sarcomeric α-actinin (red) and nuclei were counterstained with DAPI (blue). Representa
peripheral cytoplasmic TOM20 signal (N = 4) (D).3.8. Depletion of KIF5B prevented mitochondrial dispersion and limited the
respiratory increase
Silencing of Kif5bwas performed to investigatewhether KIF5B could
be responsible for the changed mitochondrial localization in PE treated
NRVCs. Transfection of speciﬁc siRNA's targeting Kif5b resulted
approximately in a 75% decrease in Kif5b mRNA levels (Fig. 8A) and
around 70% decrease in KIF5B protein levels (Fig. 8B). Interestingly,
this fully prevented PE induced dispersion of the mitochondria as isfor 72 h. Kif5bmRNA levels were measured by quantitative RT-PCR in control cells and PE
in control and PE stimulated NRVCs and a representative blot from three independent
with anti-TOM20 antibody (green). Cardiomyocytes were stained with cardiac speciﬁc
tive images are shown (B). Quantiﬁcation of the ratio in intensity of perinuclear and
Fig. 9.Kif5b silencing partially reverses PE induced effects onmitochondrial dependent cellular respiration and hypertrophy. Effects of silencing ofKif5b onPE induced cellular hypertrophy
was measured using 3H-leucine incorporation (N = 3) (A). mRNA expression levels of the hypertrophic markers Nppawere determined using qRT-PCR (N = 3) (B). Total cellular OCR
using pyruvate as a substrate was measured with sequential additions of the ATP synthase inhibitor oligomycin, the uncoupling agent FCCP and mitochondrial respiration inhibitors
antimycin A/rotenone (AR) as depicted in the graph (C). Mitochondrial speciﬁc OCR values, mitochondrial respiration, ATP-linked OCR and maximal respiration, were determined by
correcting the total OCR values for OCR values after the addition of AR. Corrected oxygen consumption data of the ﬁrst 3 measurements were averaged to yield the mitochondrial
respiration. The ATP-linked OCR, deﬁned as oligomycin-sensitive OCR, was calculated. Maximal respiration was induced by FCCP (N = 4) (D). All graphs depict means and SD,
*P b 0.05 compared to control.
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cardiomyocytes, Kif5b is involved in mitochondrial transport. We also
investigated whether this changed localization would affect cellular
respiration and hypertrophy. Silencing of Kif5b attenuated PE induced
3H-leucine incorporation, but did not prevent it (Fig. 9A) and a similar
effect was observed on cell size (1.34 ± 0.15 versus 1.21 ± 0.12 fold
increase for PE and siKif5B + PE, respectively). Pathological gene
expression was, however, not attenuated by KIF5B silencing (Fig. 9B
and Supplemental Fig. 4). Also respiration was investigated, and, since
it has been reported that the scaffold protein Daxx together with
KIF5B controls insulinmediated translocation of the glucose transporter
Glut4 in adipose cells [39], we performed these experiments with pyru-
vate as a carbon source. In control cells Kif5b silencing did not show a
signiﬁcant effect on respiration, but in PE treated NRVCs silencing of
Kif5b showed a partial diminishment (Fig. 9C and D). Similar results
were observed when glucose was used as a substrate instead of pyru-
vate, indicating that the observed effects were carbon source and
hence transporter independent (Supplemental Fig. 5). Thus, mitochon-
drial relocalization by KIF5B affects mitochondrial dependent cellular
respiration and attenuates phenylephrine induced hypertrophy.
4. Discussion
Hypertrophic stimuli induce cardiomyocyte growth, but the
biochemical and molecular alterations are clearly different between
various hypertrophic stimuli. Here we show that this is also true for
mitochondrial localization and function in vitro. Using neonatal cardio-
myocyte cultures, we were able to determine the effects of speciﬁchypertrophic stimuli onmitochondrial localization. Interestingly, stimu-
lation of NRVCs with PE resulted in an altered mitochondrial OCR and
mitochondrial localization within 24 h. Kif5bwas identiﬁed as a patho-
logical hypertrophy speciﬁc gene andwas responsible for the changes in
mitochondrial localization. Altered mitochondrial morphology and dis-
tribution are hallmarks of heart failure [37,38] and we could show that
also in pathological hypertrophy animal models, KIF5B expression was
upregulated.
Hypertrophic stimulation with PE or IGF1 resulted in the activation
of different signal transduction pathways. Moreover, in agreement
with others, only PE stimulation resulted in the expression of the fetal
gene program, a pathological hypertrophy characteristic. Here we
showed that these different stimuli also have direct, but distinct effects
on mitochondrial function and localization. Measurements of the
activities of mitochondrial complexes I and II revealed the opposite
effect in PE and IGF1 stimulated NRVCs. Whereas complex II and to a
lesser extend complex I dependent activity (state 3) were declined in
PE stimulated NRVCs, complex I dependent activity (state 3) was
increased in IGF1 treated NRVCs. Also in hypertrophic HF samples a de-
cline in activities of different complexes has been observed, but there is
limited consensus which complex activities are altered [40–42]. This is
probably related to thedifferences in the etiology and severity of disease
and it has been proven difﬁcult to uncover the processes that underlie
these changed activities. To our knowledge, we now show for the ﬁrst
time that complex I and II dependent activities can be modulated by
speciﬁc hypertrophic stimuli in vitro and this may provide an opportu-
nity to study these processes in more detail in an isolated cellular
system. This also suggests that changes in mitochondrial function can
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sarily a late stage HF phenomenon, which is in agreement with others
[43].
Despite decreased complex activities, mitochondrial respirationwas
strongly increased in PE stimulated NRVCs. In contrast no changes in
mitochondrial respiration were observed in IGF1 stimulated NRVCs.
Thus, changes inmitochondrial complex activities do not necessarily re-
ﬂect mitochondrial ﬂuxes in intact NRVCs and caution is requiredwhen
results from isolatedmitochondria are extrapolated to the whole cell or
organ. It has been proposed that in the compensated stage of hypertro-
phy, respiratory ﬂux may ﬁrst increase resulting in a gradual decline at
later stages [11]. Our increase in ﬂux in PE stimulated NRVCs may sup-
port this idea and suggest that the PE condition with increased OCR is
more comparable to early stages of cardiac pathological hypertrophy.
These results show that no simple relation exists betweenmitochondri-
al function and hypertrophy development.
Within the investigated time frame (24 h) no signiﬁcant changes in
mitochondrial biogenesis or levels of OXPHOS proteins were observed
with the two different hypertrophic stimuli. Also no signiﬁcant changes
in the expression of genes of the ETC andOXPHOSwere identiﬁed. How-
ever, we do like to note that when whole gene set analysis was per-
formed, ETC complex expression was signiﬁcantly upregulated in IGF1
stimulatedNRVCs. Theseminor differences could, however, not be iden-
tiﬁed at the protein level, and probably the 24 h stimulation is too short
to induce IGF1mediatedmitochondrial biogenesis inNRVCs. The chang-
es in complex activities are therefore likely mediated by posttransla-
tional processes, like phosphorylation, succinylation and acetylation
[44,45] and complex or supercomplex assembly [46]. In contrast to
our in vitro data, a number of studies have shown that mitochondrial
gene expression is altered in cardiac HF samples. These studies have,
however, predominantly been performed on end-stage HF cardiac tis-
sue [47,48]. A recent study, with a focus on earlier stages of HF, with
less severe cardiac remodeling showed the absence of transcriptional
changes in OXPHOS and ETC genes [5], which is in line with our
in vitro data.
IGF1 signaling is essential for mitochondrial biogenesis during phys-
iological hypertrophy stimulation in mice [49]. In a transgenic IGF1
overexpressingmousemodel PGC-1 alpha expression andmitochondri-
al protein levels were, however, not increased, but high fat diet induced
repression of mitochondrial biogenesis was prevented [50]. Thus, IGF1
alone appears not sufﬁcient for induction of mitochondrial biogenesis.
Also in this study no mitochondrial biogenesis was observed upon
IGF1 stimulation and gene expression of mitochondrial gene sets was
only slightly elevated. Mitochondrial biogenesis is thus not required
for the development of physiological hypertrophy.
Mitochondria in PE treated NRVCs showed a different localization
pattern and we identiﬁed KIF5B, a motor protein of the kinesin family
reported to control mitochondrial localization and function, to be up-
regulated under pathological hypertrophy. Moreover, depletion of
KIF5B conﬁrmed that this protein is required for the changed localiza-
tion in PE treated NRVCs. Depletion of KIF5B also resulted in diminished
hypertrophy development after PE stimulation, but could not prevent
pathological gene expression. Thus, KIF5B contributes to pathological
growth, but is not essential for the pathological response. Although we
focused here on dynamic mitochondrial localization, also effects on
other mitochondrial dynamics, namely ﬁssion and fusion have been re-
ported. Whereas Javadov et al. [51] reported altered expression of
dynamin-like protein (Drp1) and mitofusin (Mfn1/2), Pennanen et al.
[35] did not observe differences in the expression of these proteins
after hypertrophic stimulation of neonatal cardiomyocytes. Neverthe-
less they reported that norepinephrine (NE) can stimulatemitochondri-
alﬁssion by increasing the localization of Drp1 to themitochondria [35].
In our PE stimulation we did not observe changes in Drp1 and Mfn1
gene and protein expression in agreement with Pennanen et al. [35],
but did not also observe mitochondrial redistribution of Drp1 or Mfn1.
The use of PE instead of NE could potentially explain this difference,and we do not like to exclude potential alterations in mitochondrial
morphology, but the altered localization makes this difﬁcult to analyze.
Together these results show that pathological conditions can altermito-
chondrial localization and potentiallymorphology and thereby affecting
mitochondrial function. Also in heart failure patients and in animal
heart failure models changed morphology and localization of the mito-
chondria have been reported [28,37,38] and with the identiﬁcation of a
potential molecular mechanism this now warrants further investiga-
tions. In the adult cardiomyocyte the situation is, however, more com-
plex with two different types of the mitochondria, subsarcolemmal
(SS) and intermyoﬁbrillar (IFM) [52]. It is likely that other factors next
to KIF5B play a role in the proper localization of these distinctmitochon-
drial populations.
Some study limitations have to be taken into account. Although neo-
natal rat cardiomyocytes are an established in vitro hypertrophymodel,
these results cannot be directly translated to the adult heart. Themodel
has, however, a major advantage in that it allows to investigate single
stimuli independent of other contributing factors and that it is feasible
to performmitochondrial OCRmeasurements in intact NRVCs. Although
we have investigated the levels of some mitochondrial complex pro-
teins, to exclude changes in biogenesis, we have not investigated com-
plex formation or post-translational modiﬁcations. Considering our
results elaborate mass spectrometry analysis might be an interesting
next step.
In conclusion, we provide for the ﬁrst time an in vitro model of mi-
tochondrial dysfunction and changed dynamic localization in patholog-
ical and physiological cardiac hypertrophy. We identify KIF5B as a gene
that is upregulated exclusively in pathological hypertrophy with a role
in mitochondrial localization and function.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2016.04.005.
Disclosures
The authors declare no conﬂict of interest.
Financial support
R.A de Boer is supported by the Innovational Research Incentives
Schemeprogramof theNetherlandsOrganisation for Scientiﬁc Research
[Vidi grant 917.13.350].
Acknowledgments
We like to thank Sarah Meijer, Reinier Bron and Louise vanWijk for
helpwithWestern blotting,microscopy, cell counting and RNA analysis.
We like to thank Moshin Kahn for help with generating heat-maps in
“R”. We like to thank Laura Meems for supplying us with RNA of animal
experiments.
References
[1] S.P. Barry, S.M. Davidson, P.A. Townsend, Molecular regulation of cardiac hypertro-
phy, Int. J. Biochem. Cell Biol. 40 (2008) 2023–2039.
[2] N. Frey, H.A. Katus, E.N. Olson, J.A. Hill, Hypertrophy of the heart: a new therapeutic
target? Circulation 109 (2004) 1580–1589.
[3] B.C. Bernardo, K.L. Weeks, L. Pretorius, J.R. McMullen, Molecular distinction between
physiological and pathological cardiac hypertrophy: experimental ﬁndings and
therapeutic strategies, Pharmacol. Ther. 128 (2010) 191–227.
[4] R.A. De Boer, Y.M. Pinto, D.J. Van Veldhuisen, The imbalance between oxygen de-
mand and supply as a potential mechanism in the pathophysiology of heart failure:
the role of microvascular growth and abnormalities, Microcirculation 10 (2003)
113–126.
[5] L. Lai, T.C. Leone, M.P. Keller, O.J. Martin, A.T. Broman, J. Nigro, et al., Energymetabol-
ic reprogramming in the hypertrophied and early stage failing heart: a multisystems
approach, Circ. Heart Fail. 7 (2014) 1022–1031.
[6] P.C. Kienesberger, T. Pulinilkunnil, J. Nagendran, J.R. Dyck, Myocardial triacylglycerol
metabolism, J. Mol. Cell. Cardiol. 55 (2013) 101–110.
[7] S.C. Kolwicz Jr., R. Tian, Glucose metabolism and cardiac hypertrophy, Cardiovasc.
Res. 90 (2011) 194–201.
81W. Tigchelaar et al. / Journal of Molecular and Cellular Cardiology 97 (2016) 70–81[8] J.J. Lehman, D.P. Kelly, Gene regulatory mechanisms governing energy metabolism
during cardiac hypertrophic growth, Heart Fail. Rev. 7 (2002) 175–185.
[9] B.T. O'Neill, J. Kim, A.R. Wende, H.A. Theobald, J. Tuinei, J. Buchanan, et al., A
conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochon-
drial adaptations that accompany physiological cardiac hypertrophy, Cell Metab. 6
(2007) 294–306.
[10] E.D. Abel, T. Doenst, Mitochondrial adaptations to physiological vs. pathological
cardiac hypertrophy, Cardiovasc. Res. 90 (2011) 234–242.
[11] M.G. Rosca, B. Tandler, C.L. Hoppel, Mitochondria in cardiac hypertrophy and heart
failure, J. Mol. Cell. Cardiol. 55 (2013) 31–41.
[12] B. Lu, H. Mahmud, A.H. Maass, B. Yu, W.H. van Gilst, R.A. de Boer, et al., The Plk1
inhibitor BI 2536 temporarily arrests primary cardiac ﬁbroblasts in mitosis and
generates aneuploidy in vitro, PLoS One 5 (2010), e12963.
[13] B. Lu, H. Yu, M. Zwartbol, W.P. Ruifrok, W.H. van Gilst, R.A. de Boer, et al., Identiﬁca-
tion of hypertrophy- and heart failure-associated genes by combining in vitro and
in vivo models, Physiol. Genomics 44 (2012) 443–454.
[14] R.A. de Boer, S. Pokharel, M. Flesch, D.A. van Kampen, A.J. Suurmeijer, F. Boomsma,
et al., Extracellular signal regulated kinase and SMAD signaling both mediate the
angiotensin II driven progression towards overt heart failure in homozygous
TGR(mRen2)27, J. Mol. Med. 82 (2004) 678–687.
[15] O.J. Muller, M. Lange, H. Rattunde, H.P. Lorenzen, M. Muller, N. Frey, et al., Transgenic
rat hearts overexpressing SERCA2a show improved contractility under baseline
conditions and pressure overload, Cardiovasc. Res. 59 (2003) 380–389.
[16] J.K. Salabei, A.A. Gibb, B.G. Hill, Comprehensive measurement of respiratory activity
in permeabilized cells using extracellular ﬂux analysis, Nat. Protoc. 9 (2014)
421–438.
[17] W. Tigchelaar, H. Yu, A.M. de Jong, W.H. van Gilst, P. van der Harst, B.D.
Westenbrink, et al., Loss of mitochondrial exo/endonuclease EXOG affects
mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy,
Am. J. Physiol. Cell Physiol. 308 (2015) C155–C163.
[18] K. Lin, H. Kools, P.J. de Groot, A.K. Gavai, R.K. Basnet, F. Cheng, et al., MADMAX —
management and analysis database for multiple ~omics experiments, J. Integr.
Bioinform. 8 (2011) 160 (jib-2011-160).
[19] M.A. Sartor, C.R. Tomlinson, S.C. Wesselkamper, S. Sivaganesan, G.D. Leikauf, M.
Medvedovic, Intensity-based hierarchical Bayes method improves testing for
differentially expressed genes inmicroarray experiments, BMC Bioinf. 7 (2006) 538.
[20] J.D. Storey, R. Tibshirani, Statistical signiﬁcance for genomewide studies, Proc. Natl.
Acad. Sci. U. S. A. 100 (2003) 9440–9445.
[21] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources, Nat. Protoc. 4 (2009) 44–57.
[22] A. Subramanian, P. Tamayo, V.K.Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, et al.,
Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression proﬁles, Proc. Natl. Acad. Sci. U. S. A. 102 (2005)
15545–15550.
[23] A.M. De Jong, I.C. Van Gelder, I. Vreeswijk-Baudoin, M.V. Cannon, W.H. Van Gilst,
A.H. Maass, Atrial remodeling is directly related to end-diastolic left ventricular
pressure in a mouse model of ventricular pressure overload, PLoS One 8 (2013),
e72651.
[24] M.A. Lee, M. Bohm, M. Paul, M. Bader, U. Ganten, D. Ganten, Physiological
characterization of the hypertensive transgenic rat TGR(mREN2)27, Am. J. Phys.
270 (1996) E919–E929.
[25] V.G. Sharov, A.V. Todor, N. Silverman, S. Goldstein, H.N. Sabbah, Abnormal
mitochondrial respiration in failed human myocardium, J. Mol. Cell. Cardiol. 32
(2000) 2361–2367.
[26] C.C. Strom, M. Aplin, T. Ploug, T.E. Christoffersen, J. Langfort, M. Viese, et al.,
Expression proﬁling reveals differences in metabolic gene expression between
exercise-induced cardiac effects and maladaptive cardiac hypertrophy, FEBS J. 272
(2005) 2684–2695.
[27] G.W. Dorn II, Mitochondrial dynamics in heart disease, Biochim. Biophys. Acta 2013
(1833) 233–241.
[28] G.W. Dorn II, Mitochondrial dynamism and heart disease: changing shape and
shaping change, EMBO Mol. Med. 7 (2015) 865–877.
[29] M. Yano, M. Kanazawa, K. Terada, M. Takeya, N. Hoogenraad, M. Mori, Functional
analysis of human mitochondrial receptor Tom20 for protein import into
mitochondria, J. Biol. Chem. 273 (1998) 26844–26851.
[30] D.J. Pagliarini, S.E. Calvo, B. Chang, S.A. Sheth, S.B. Vafai, S.E. Ong, et al., A mitochon-
drial protein compendium elucidates complex I disease biology, Cell 134 (2008)
112–123.[31] L.L. Yao, Y.G. Wang, X.J. Liu, Y. Zhou, N. Li, J. Liu, et al., Phenylephrine protects
cardiomyocytes from starvation-induced apoptosis by increasing glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) activity, J. Cell. Physiol. 227 (2012)
3518–3527.
[32] H. Zhu, S. McElwee-Witmer, M. Perrone, K.L. Clark, A. Zilberstein, Phenylephrine
protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-
induced apoptosis, Cell Death Differ. 7 (2000) 773–784.
[33] Y. Tanaka, Y. Kanai, Y. Okada, S. Nonaka, S. Takeda, A. Harada, et al., Targeted
disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal
perinuclear clustering of mitochondria, Cell 93 (1998) 1147–1158.
[34] L. Fang, X.L. Moore, X.M. Gao, A.M. Dart, Y.L. Lim, X.J. Du, Down-regulation of
mitofusin-2 expression in cardiac hypertrophy in vitro and in vivo, Life Sci. 80
(2007) 2154–2160.
[35] C. Pennanen, V. Parra, C. Lopez-Crisosto, P.E. Morales, A. Del Campo, T. Gutierrez,
et al., Mitochondrial ﬁssion is required for cardiomyocyte hypertrophy mediated
by a Ca2+-calcineurin signaling pathway, J. Cell Sci. 127 (2014) 2659–2671.
[36] Y. Tang, C. Mi, J. Liu, F. Gao, J. Long, Compromised mitochondrial remodeling in
compensatory hypertrophied myocardium of spontaneously hypertensive rat,
Cardiovasc. Pathol. 23 (2014) 101–106.
[37] L. Chen, Q. Gong, J.P. Stice, A.A. Knowlton, Mitochondrial OPA1, apoptosis, and heart
failure, Cardiovasc. Res. 84 (2009) 91–99.
[38] J. Schaper, R. Froede, S. Hein, A. Buck, H. Hashizume, B. Speiser, et al., Impairment of
the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomy-
opathy, Circulation 83 (1991) 504–514.
[39] V.S. Lalioti, S. Vergarajauregui, Y. Tsuchiya, S. Hernandez-Tiedra, I.V. Sandoval, Daxx
functions as a scaffold of a protein assembly constituted by GLUT4, JNK1 and KIF5B,
J. Cell. Physiol. 218 (2009) 416–426.
[40] A.M. Cordero-Reyes, A.A. Gupte, K.A. Youker, M. Loebe, W.A. Hsueh, G. Torre-
Amione, et al., Freshly isolated mitochondria from failing human hearts exhibit
preserved respiratory function, J. Mol. Cell. Cardiol. 68 (2014) 98–105.
[41] J. Marin-Garcia, M.J. Goldenthal, G.W. Moe, Abnormal cardiac and skeletal muscle
mitochondrial function in pacing-induced cardiac failure, Cardiovasc. Res. 52
(2001) 103–110.
[42] M. Schoepe, A. Schrepper, M. Schwarzer, M. Osterholt, T. Doenst, Exercise can induce
temporarymitochondrial and contractile dysfunction linked to impaired respiratory
chain complex activity, Metabolism 61 (2012) 117–126.
[43] H. Lemieux, S. Semsroth, H. Antretter, D. Hofer, E. Gnaiger, Mitochondrial respiratory
control and early defects of oxidative phosphorylation in the failing human heart,
Int. J. Biochem. Cell Biol. 43 (2011) 1729–1738.
[44] A. Hofer, T. Wenz, Post-translational modiﬁcation of mitochondria as a novel mode
of regulation, Exp. Gerontol. 56 (2014) 202–220.
[45] K. Shinmura, Post-translational modiﬁcation ofmitochondrial proteins by caloric re-
striction: possible involvement in caloric restriction-induced cardioprotection,
Trends Cardiovasc. Med. 23 (2013) 18–25.
[46] N.V. Dudkina, R. Kouril, K. Peters, H.P. Braun, E.J. Boekema, Structure and function of
mitochondrial supercomplexes, Biochim. Biophys. Acta 2010 (1797) 664–670.
[47] V. Beisvag, O.J. Kemi, I. Arbo, J.P. Loennechen, U. Wisloff, M. Langaas, et al., Patholog-
ical and physiological hypertrophies are regulated by distinct gene programs, Eur. J.
Cardiovasc. Prev. Rehabil. 16 (2009) 690–697.
[48] I. Drozdov, A. Didangelos, X. Yin, A. Zampetaki, M. Abonnenc, C. Murdoch, et al.,
Gene network and proteomic analyses of cardiac responses to pathological and
physiological stress, Circ. Cardiovasc. Genet. 6 (2013) 588–597.
[49] C. Riehle, A.R. Wende, Y. Zhu, K.J. Oliveira, R.O. Pereira, B.P. Jaishy, et al., Insulin
receptor substrates are essential for the bioenergetic and hypertrophic response
of the heart to exercise training, Mol. Cell. Biol. 34 (2014) 3450–3460.
[50] Y. Zhang, M. Yuan, K.M. Bradley, F. Dong, P. Anversa, J. Ren, Insulin-like growth
factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of
insulin signaling and mitochondrial function, Hypertension 59 (2012) 680–693.
[51] S. Javadov, V. Rajapurohitam, A. Kilic, J.C. Hunter, A. Zeidan, N. Said Faruq, et al.,
Expression of mitochondrial fusion–ﬁssion proteins during post-infarction
remodeling: the effect of NHE-1 inhibition, Basic Res. Cardiol. 106 (2011) 99–109.
[52] J.M. Hollander, D. Thapa, D.L. Shepherd, Physiological and structural differences in
spatially distinct subpopulations of cardiac mitochondria: inﬂuence of cardiac
pathologies, Am. J. Physiol. Heart Circ. Physiol. 307 (2014) H1–14.
